



# AIBL/Australian ADNI: CLINICAL UPDATE


---

Dr Kathryn Ellis

AIBL national manager and cognitive stream co-leader

*On behalf of the AIBL management team*

**OVERVIEW:** AIBL is the most comprehensive, longitudinal study of its kind in Australia, and aims to discover a way to develop biomarkers, diagnose patients earlier and prevent disease onset.



# AIBL: Longitudinal cohort

## Baseline

(1,112)

Psychometrics  
Bloods  
MRI/PET  
Lifestyle  
Genotype

Non-Return:  
112  
Deceased:  
NMC 2  
SMC 4  
MCI 5  
AD 17



## 18M

(972)

Psychometrics  
Bloods  
MRI/PET

Non-Return:  
120  
Deceased:  
NMC 3  
SMC 3  
MCI 4  
AD 34



## 36M

(824)

Psychometrics  
Bloods  
MRI/PET


Returned at 36 months  
16



1 Non-AD Dementia

5 Non-AD Dementia

# Healthy to MCI transition over 18 and 36 months




Survival analysis was conducted to examine transition rates

HC to MCI transition was 2.5% at 18-months (17 cases)

HC to MCI transition was 5.7% by 36-months (additional 18 cases).

# MCI to AD transition over 18 and 36 months



MCI to AD transition was 30.5% at 18-months (32 cases)

MCI to AD transition was 80% by 36-months (additional 16 cases).

By the 36 month time-point only 26 of the original 133 MCI cases were still in this category.


# Comparing “stable” and “transition” groups

Demographic characteristics of “stable” groups (those who remain in the same category) and “transition” groups” (those who change category towards disease classifications) over the initial 18-month period

	HC Stable (N = 685)	HC transitioned to MCI (N = 17)	MCI stable (N = 63)	MCI transitioned to AD (N = 32)
Age (years)	69.7 (6.8)	71.7 (7.0)	75.5 (7.7)	76.4 (7.3)
Percentage female	58.7%	41.2%	53.8%	59.4%
Percentage APOE ε4	26.3%	47.1%	36.9%*	78.1%*
Education (<=12 years)	45.2%	70.6%	52.3%	68.8%
Premorbid IQ	43.1 (6.0)	42.8 (5.4)	40.2 (9.3)	41.3 (7.4)
HADS-D	2.6 (2.2)	2.8 (2.5)	3.7 (2.8)	3.2 (2.2)
HADS-A	4.3 (2.9)	4.5 (2.1)	5.0 (3.0)	4.5 (2.5)


- A number of collaborative projects examining conversion/transition from HC within AIBL
- Evidence of bimodality in AIBL HC group – higher performers less likely to convert to MCI or AD - using a number of statistical models
- Cognition combined with biomarkers is aiding in detection of “at risk” HC population

# Magnitude of decline over 18 months (ApoE ε4+)








# Magnitude of decline over 18 months (High A $\beta$ )



- Non *APOE*  $\epsilon$ 4 carriers who were engaged in high levels of exercise had significantly lower plasma A $\beta$ <sub>1-42/1-40</sub> ratio.
- *APOE*  $\epsilon$ 4 carriers who were engaged in high levels of exercise showed lower [<sup>11</sup>C] PiB PET levels than  $\epsilon$ 4 carriers with lower levels of exercise.
- This may reflect different mechanisms at play for *APOE*  $\epsilon$ 4 carriage and A $\beta$  in the brain versus the periphery.



# Higher Medeteranian Diet (MeDi) Score is associated with lower PiB SUVR



Controlling for age, APOE genotype, gender and years of education.

## aibl ROCS

Characterize the cognitive performance of a group of 205 healthy older adults, and adults with MCI, and AD over short test-retest intervals (10 times over 18-months).

## aibl ACTIVE

RCT of physical activity to delay the progression of white matter hyperintensities on MRI in older adults at risk of cognitive decline

## aibl WHAP

Prospective data from midlife, 3 cognitive timepoints over 20 years prior. 100 participants seen so far 80% retention from 2002 cognitive test

# Acknowledgements and thanks



AIBL is a large collaborative study and a complete list of contributors can be found at [www.aibl.csiro.au](http://www.aibl.csiro.au)



This research is funded in part by the Science and Industry Endowment Fund.



We thank all who took part in the study.



SCIENCE AND  
INDUSTRY  
ENDOWMENT  
FUND